SEC Form 4 · accession 0001193125-26-380277
Revolution Medicines, Inc. · RVMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lorence H. Kim
Director
Period of report
Aug 31, 2026
Accepted (ET)
Sep 2, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001628171
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF3 | Aug 31, 2026 | S | 300 | $200.56 | D | 72,790 | I | Trust |
| Common StockF4,F3 | Aug 31, 2026 | S | 6,597 | $201.4729 | D | 66,193 | I | Trust |
| Common StockF5,F3 | Aug 31, 2026 | S | 12,919 | $202.4819 | D | 53,274 | I | Trust |
| Common StockF6,F3 | Aug 31, 2026 | S | 26,160 | $203.5483 | D | 27,114 | I | Trust |
| Common StockF7,F3 | Aug 31, 2026 | S | 7,271 | $204.3501 | D | 19,843 | I | Trust |
| Common StockF8,F3 | Aug 31, 2026 | S | 2,128 | $205.1879 | D | 17,715 | I | Trust |
| Common StockF9,F3 | Aug 31, 2026 | S | 625 | $206.154 | D | 17,090 | I | Trust |
| Common StockF1 | holding | — | — | — | 1,191 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 1,191 restricted stock units.
- F2Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026.
- F3Shares held by the Lorence Kim Revocable Trust (the "Trust"). Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13.
- F4The transaction was executed in multiple trades at prices ranging from $201.00 to $201.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5The transaction was executed in multiple trades at prices ranging from $202.00 to $202.9956, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6The transaction was executed in multiple trades at prices ranging from $203.0055 to $203.9968, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F7The transaction was executed in multiple trades at prices ranging from $204.00 to $204.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F8The transaction was executed in multiple trades at prices ranging from $205.00 to $205.93, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F9The transaction was executed in multiple trades at prices ranging from $206.02 to $206.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.